.
MergerLinks Header Logo

Announced

Completed

ARCH Venture Partners and Cormorant Asset Management led a $200m Series B round for Erasca.

Financials

Edit Data
Transaction Value£161m
Consideration TypeCash
Capital Owned-
Capital Bid For-
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

United States

Private

Private Equity

Single Bidder

Completed

cancer treatment

Venture Capital

Biotechnology

Acquisition

oncology

Minority

Friendly

Synopsis

Edit

ARCH Venture Partners and Cormorant Asset Management led a $200m Series B round for Erasca, a biotechnology company in San Diego, California. New investors participating in this financing include global Singapore-based investor EDBI, Invus, Terra Magnum Capital Partners, and other private and strategic investors. Existing investors City Hill Ventures, Colt Ventures and LifeSci Venture Partners also participated meaningfully in the round. "We are pleased to continue backing Erasca’s terrific team and bold mission. Cancer is a formidable disease. Therefore, Erasca’s team has built an impressive portfolio of potentially first-in-class and best-in-class assets, including successful in-licensing of several key programs to address significant unmet needs. The company has the talent, assets and perseverance to substantially change the trajectory of cancer treatment and improve patient outcomes in a meaningful way," Kristina Burow, ARCH Venture Partners Managing Director.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US